## Philadelphia Chromosome–Positive B-ALL: TKI Selection **Key Point:** Ph+ B-ALL (t(9;22) with BCR-ABL1 fusion) requires dual therapy: chemotherapy + tyrosine kinase inhibitor (TKI). First-generation TKI imatinib remains the standard induction choice. ### BCR-ABL1 Pathophysiology The Philadelphia chromosome produces a constitutively active tyrosine kinase that drives uncontrolled proliferation. TKIs block this kinase activity and restore apoptosis. ### TKI Comparison in Ph+ B-ALL | TKI | Generation | CNS Penetration | Potency | Resistance Profile | Role in B-ALL | |-----|-----------|-----------------|---------|-------------------|---------------| | **Imatinib** | 1st | Moderate | Standard | BCR-ABL1 WT sensitive | **First-line induction** | | Nilotinib | 2nd | Poor | Higher | Resistant mutants | Salvage/relapse | | Dasatinib | 2nd | Excellent | Higher | Resistant mutants | CNS-positive disease | | Ponatinib | 3rd | Moderate | Highest | Pan-resistant | T315I mutants only | **High-Yield:** Imatinib + chemotherapy (e.g., hyper-CVAD or similar) achieves **85–90% complete remission** in newly diagnosed Ph+ B-ALL. Addition of imatinib to chemotherapy has transformed Ph+ B-ALL from a dismal prognosis to one with long-term survival rates >50%. ### Clinical Pearl - Imatinib is preferred in induction because it has the longest clinical track record, lowest toxicity, and proven efficacy in combination with chemotherapy. - Second-generation TKIs (nilotinib, dasatinib) are reserved for: - Imatinib resistance or intolerance. - CNS involvement (dasatinib preferred for superior CNS penetration). - Relapsed/refractory disease. - Ponatinib is reserved exclusively for T315I-mutant BCR-ABL1, which confers resistance to all other TKIs. ### Monitoring During Therapy - BCR-ABL1 transcript levels (RT-PCR) at 3, 6, and 12 months. - Mutational analysis if loss of response occurs. [cite:Harrison 21e Ch 110]
Sign up free to access AI-powered MCQ practice with detailed explanations and adaptive learning.